检索结果-南通市图书馆

Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma:an open-label,multicenter,phase 1 study(MMY1010)

引用

Blood Science 2024年第3期6卷 42-47页

作者： Gang An Zheng Ge Hongmei Jing Jing Liu Guoping Yang Ru Feng Zhongyuan Xu Ming Qi Jianping Wang Juanjuan Song Wei Zhou Binbin Sun Dian Zhu Xi Chen Canchan Cui Lugui Qiu National Clinical Research Center for Hematological Disorders State Key Laboratory of Experimental HematologyInstitute of Hematology and Blood Diseases HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeTianjin 300020China Department of Hematology Zhongda Hospital Southeast UniversityNanjing 210009China Peking University Third Hospital Beijing 100191China Department of Hematology The Third Xiangya Hospital of Central South UniversityChangsha 410013China Department of Hematology Nanfang Hospital of Southern Medical UniversityGuangzhou 510515China Phase 1 Clinical Trial Department Nanfang Hospital of Southern Medical UniversityGuangzhou 510515China Janssen Research&Development LLCSpring HousePA 19477USA Janssen Research&Development LLCBeijing 100025China Janssen Research&Development LLCShanghai 200231Chin

Despite recent progress in multiple myeloma(MM)treatments,most patients will relapse and require additional *** daratumumab,a human IgGκmonoclonal antibody targeting CD38,has shown good efficacy in the treatment of MM.A subcutaneous version of daratumumab was formulated to reduce the burden of intravenous *** aimed to investigate the efficacy and safety of subcutaneous daratumumab in Chinese patients with relapsed/refractory MM based on the demonstrated noninferiority of subcutaneous daratumumab to intravenous daratumumab,with a shorter administration time and reduced infusion-related reaction rate in global *** phase 1,multicenter study(MMY1010;*** Identifier:NCT04121260)evaluated subcutaneous daratumumab in Chinese patients with relapsed/refractory MM after 1 prior line(n=1)or≥2 prior lines(n=20)of therapy,including a proteasome inhibitor and an immunomodulatory *** endpoints were pharmacokinetics and ***(standard deviation)maximum trough concentration of daratumumab was 826(335)μg/mL,which was consistent with prior studies of subcutaneous daratumumab and intravenous *** was consistent with safety profiles observed in other daratumumab studies,with no new safety concerns *** of infusion-related reactions and injection-site reactions were low and consistent with other subcutaneous daratumumab *** a median follow-up of 7.5 months,the overall response rate was 57.1%,with a very good partial response or better rate of 38.1%and complete response or better rate of 19.0%.Our results demonstrate a favorable benefit/risk profile of subcutaneous daratumumab in Chinese patients with relapsed/refractory MM,potentially impacting clinical administration of daratumumab in this population.

关键词： Chinese Daratumumab Multiple myeloma Pharmacokinetic relapse/refractory Safety Subcutaneous

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Overall Survival and Health Care Costs of Medicare Patients with Previously Treated Chronic Lymphocytic Leukemia

引用

Journal of Cancer Therapy 2018年第7期9卷 576-587页

作者： Carolina Reyes Genevieve Gauthier Sherry Shi Annie Guerin Genentech Inc. South San Francisco CA USA Analysis Group Inc. Montreal Canada

Background: Bendamustine-based regimens are often used in the management of patients with chronic lymphocytic leukemia (CLL) but few studies have analyzed the comorbidity- and/or adverse event (CAE)-related healthcare costs in patients receiving these regimens in a real-world setting. Aims: To describe all-cause and CAE-related healthcare costs in relapse/refractory (R/R) elderly patients with CLL treated with bendamustine-based regimens in a real-world setting. Methods: Adult patients with R/R CLL who received bendamustine-based regimens on/after January 2010 were selected from the Medicare Limited Data Set (LDS) 5% Standard Analytic Files. Selected patients were classified into cohorts based on the two most prevalent bendamustine-based regimens observed (index treatment): 1) bendamustine + rituximab (BR cohort) and 2) bendamustine monotherapy (B-mono cohort). For each cohort, all-cause and CAE-related healthcare costs, while on treatment, were reported per-patient-per-month (PPPM). Overall survival (OS) rates following initiation of the index treatment were described using age- and gender-adjusted Kaplan-Meier curves. Results: A total of 275 patients were included in the BR cohort and 100 patients in the B-mono cohort. Most patients were male and the mean age was approximately 75 years old. During treatment, total all-cause healthcare costs were $14,520 PPPM for the BR cohort and $13,125 PPPM for the B-mono cohort—outpatient costs (mainly driven by CLL-drug costs) represented 86.1% of the total all-cause healthcare costs for the BR cohort and 69.8% for the B-mono cohort. CAE costs accounted for 58.3% of the total all-cause healthcare costs for the BR cohort and 66.9% for the B-mono cohort. Median OS was 35 months in the BR cohort and 21 months in the B-mono cohort. Conclusion: In this population of elderly patients with R/R CLL treated with bendamustine-based regimens, CAEs were common and translated into important medical costs. Median OS was also relatively shor

关键词： Chronic Lymphocytic Leukemia relapse/refractory Bendamustine Economic Burden Overall Survival Adverse Events

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：